Frontiers Production Office. (2022). Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab. Frontiers Media S.A..
Chicago Style (17th ed.) CitationFrontiers Production Office. Erratum: Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab. Frontiers Media S.A., 2022.
MLA (9th ed.) CitationFrontiers Production Office. Erratum: Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab. Frontiers Media S.A., 2022.
Warning: These citations may not always be 100% accurate.